EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access

Outcomes After Intratumoral Delivery of Immunotherapy in Breast Cancer

Camille C Baumrucker iD, Nicole Harris, Paige Aiello, Junmin Whiting, Weihong Sun, Hatem Soliman, Hyo Han, Ricardo Costa, Brian J Czerniecki, Marie Catherine Lee

Journal of Surgical Oncology · 2026

DOI: 10.1002/jso.70287 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Surgical Oncology, 2026. Verfasst von Camille C Baumrucker und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Oncology, H. Lee Moffitt Cancer Center, Tampa, Florida, USA. Hauptthemen laut MEDLINE: Antineoplastic Agents, Immunological, Breast Neoplasms, Immunotherapy, Triple Negative Breast Neoplasms. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immunotherapy is a growing treatment option for challenging breast cancer (BC) subtypes. Systemic administration can have significant adverse events (AEs), prompting interest in intratumoral injection. We evaluated the safety and feasibility of intratumoral injections at our institution.

Methods

This is an IRB‐approved retrospective review of neoadjuvant patients who received intratumoral talimogene laherparepvec (TVEC) (NCT02779855) for triple negative breast cancer (TNBC), dendritic cells (DC1) for HER2+ (NCT05325632), HER2 + /ER‐ (NCT03387553), or TNBC (NCT05504707), or Voyager V1 virus (VV1) (NCT01042379) for high‐risk lesions on ISPY2. This study outlines the safety and feasibility of intratumoral injections assessed by AEs, adherence to therapy, and ultrasound guidance.

Results

The study included 111 female patients (mean age 51; range 26‐80). Forty‐seven (42.3%) received TVEC, 62 (55.9%) received DC1, and 2 (1.8%) received VV1. Three patients missed one injection; 110 patients had ultrasound‐guided injections. Mean neoadjuvant therapy length was 172 days (range 127‐244). Local AEs included pain (20.7%), injection site reaction (27.9%), and hematoma (5.4%). Systemic AEs were reported more frequently, most commonly chills (52.3%), headache (39.6%), and fever (36.8%).

Discussion

Intratumoral IT injection is a viable treatment option that may minimize systemic exposure while maintaining therapeutic efficacy. Breast surgeons can play a role in intratumoral IT in BC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Agents, ImmunologicalBreast NeoplasmsImmunotherapyTriple Negative Breast NeoplasmsAdultAgedAged, 80 and overFemaleHumansMiddle AgedDendritic CellsInjections, IntralesionalOncolytic VirotherapyRetrospective StudiesBiological ProductsHerpesvirus 1, Human

Stichwörter der Autor:innen

breast immunotherapydendritic cellsintratumoral injectiononcolytic virus

Substanzen

Antineoplastic Agents, Immunologicaltalimogene laherparepvecBiological Products

Autor:innen und Institutionen

  • Department of Breast Oncology, H. Lee Moffitt Cancer Center, Tampa, Florida, USA.
  • Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center, Tampa, Florida, USA.

ORCID-Profile: Camille C Baumrucker

Zitieren

APA

Baumrucker, C. C., Harris, N., Aiello, P., Whiting, J., Sun, W., Soliman, H., Han, H., Costa, R., Czerniecki, B. J., & Lee, M. C. (2026). Outcomes After Intratumoral Delivery of Immunotherapy in Breast Cancer. Journal of Surgical Oncology. https://doi.org/10.1002/jso.70287

Vancouver

Baumrucker CC, Harris N, Aiello P, Whiting J, Sun W, Soliman H, et al. Outcomes After Intratumoral Delivery of Immunotherapy in Breast Cancer. Journal of Surgical Oncology. 2026. doi:10.1002/jso.70287

BibTeX
@article{Baumrucker2026,
  author = {Baumrucker, Camille C and Harris, Nicole and Aiello, Paige and Whiting, Junmin and Sun, Weihong and Soliman, Hatem and Han, Hyo and Costa, Ricardo and Czerniecki, Brian J and Lee, Marie Catherine},
  title = {Outcomes After Intratumoral Delivery of Immunotherapy in Breast Cancer},
  journal = {Journal of Surgical Oncology},
  year = {2026},
  doi = {10.1002/jso.70287}
}
Kostenlos starten →